Navigation Links
Novel Mass Spectrometry-based Assay Reveals Degradation and Low Levels of Bioactive B-type Natriuretic Peptide (BNP) in Patients with Heart Failure
Date:10/16/2008

TEMPE, Ariz., Oct. 16 /PRNewswire/ -- A team of researchers from Intrinsic Bioprobes Inc. has reported on a novel quantitative mass spectrometry immunoassay for the detection of bioactive B-type natriuretic peptide (BNP), in an article published online on Oct. 14 in the journal of Circulation: Heart Failure. In collaboration with colleagues from Scios Inc. in Fremont, Christ Hospital in Cincinnati, and Medivation Inc. in San Francisco, the team discovered very low concentration of bioactive BNP in plasma obtained from patients with heart failure, and presented direct structural evidence for several proteolytically degraded forms of BNP in these patients.

"Commercially available assays for immunoreactive BNP do not reflect the bioactivity of the natriuretic peptide system, since they measure both unprocessed, inactive proBNP and mature BNP 1-32," says Eric Niederkofler, Ph.D., the principal investigator from Intrinsic Bioprobes. BNP is synthesized as a 108 amino acid propeptide and proteolytically processed to release an inactive 76 amino acid N-terminal fragment and bioactive mature BNP 1-32 into the bloodstream. "This is the first assay capable of detecting and quantifying BNP 1-32 alone. Furthermore, the assay allowed us to study the molecular complexity of BNP degradation, revealing rapid in vitro degradation of BNP 1-32, and necessitating certain preservation protocol during blood collection and subsequent sample handling," adds Niederkofler.

"This work is going to add greater clarity to how clinicians and researchers approach natriuretic peptides and heart failure," says Dr. Roger Mills, from Ortho McNeil Jannsen Scientific Affairs. "The results may provide an explanation for the 'natriuretic paradox' of increased natriuretic hormone levels with blunted effects in heart failure patients."

Intrinsic Bioprobes Inc. is a privately held Biotechnology Company focused on developing mass spectrometry-based assays and platforms for rapid and sensitive protein biomarker analysis. The company's proprietary technologies consist of Mass Spectrometric Immunoassay (MSIA), a high-performance immunoassay combining micro-scale immunoaffinity capture and mass spectrometry for high throughput analysis of proteins from complex biological matrices, and Bioreactive Mass Spectrometer Probes (BRP), devices for rapid, sensitive and accurate protein characterization. These root technologies are incorporated into the MASSAY System, a high throughput mass spectrometry platform for rapid proteome analysis. For more information about Intrinsic Bioprobes Inc., please visit http://www.intrinsicbio.com.

Contact:

Intrinsic Bioprobes Inc.

Monte Cain, Director of Business Development

Tel.: (480) 804-1778

E-mail: monte@intrinsicbio.com

This release was issued through eReleases(TM). For more information, visit http://www.ereleases.com.


'/>"/>
SOURCE Intrinsic Bioprobes Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Morria Biopharmaceuticals Plc Announces Results From its Pre-Clinical Screening of Novel Anti-Inflammatory Compounds
2. Arisyn Therapeutics Inc. Acquires Highly Novel Portfolio of Therapeutic Small Molecules for Infectious Disease and Cancer
3. Spherics, Inc. Announces Sale of Novel Proprietary Bioadhesive Polymers and Oral Drug Delivery System
4. CV Therapeutics Initiates Phase 1 Clinical Trial of CVT-3619, a Novel Potential Treatment for Cardiometabolic Diseases
5. Pressure BioSciences, Inc. Releases Novel, PCT-dependent Sample Preparation Kit for Systems Biology Studies
6. UC Riverside researcher develops novel method to grow human embryonic stem cells
7. Lixte Biotechnology Holdings Announces Filing of a New Patent Application for Cancer Therapy Based on Targeting a Biomarker by Novel Investigational Agents
8. John Grisham Joins Focused Ultrasound Surgery Foundation Board, Citing Novel Technologys Potential to Help Millions of Patients
9. Tree branching key to efficient flow in nature and novel materials
10. Genetic Engineering & Biotechnology News reports on novel hit-to-lead drug discovery
11. GEN Reports on Novel Hit-to-Lead Drug Discovery Strategies
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/28/2017)... , ... April 28, 2017 , ... ... organization (CRO) has validated a 0.2 ng/mL lower limit (LLOQ) assay for nicotine ... 0.5 ng/mL LLOQ assay, the ultra-low trace nicotine assay meets additional needs of ...
(Date:4/27/2017)... ... April 27, 2017 , ... ... today announced their digital pathology technology has the potential to eliminate subjectivity in ... centers in The Netherlands as part of the 2017 ISBI CAMELYON Digital ...
(Date:4/27/2017)... ... April 27, 2017 , ... Arrowhead Publishers is pleased to ... coming to San Diego, CA on September 27-28, 2017. Leaders from the pharmaceutical, ... advances in the treatment of various types of pain. There are also extended ...
(Date:4/27/2017)... Orleans, La. (PRWEB) , ... ... ... Monitoring Technologies today announced a comprehensive rebrand and a name change to ... for the industrial and laboratory monitoring of polymer and biopharmaceutical manufacturing processes ...
Breaking Biology Technology:
(Date:4/11/2017)... , April 11, 2017 NXT-ID, Inc. ... technology company, announces the appointment of independent Directors Mr. ... to its Board of Directors, furthering the company,s corporate governance ... Gino ... we look forward to their guidance and benefiting from their ...
(Date:4/5/2017)... NEW YORK , April 5, 2017 ... security, is announcing that the server component of the ... is known for providing the end-to-end security architecture that ... customers. HYPR has already secured over 15 ... system makers including manufacturers of connected home product suites ...
(Date:4/3/2017)... , April 3, 2017  Data captured ... engineering platform, detected a statistically significant association ... prior to treatment and objective response of ... potential to predict whether cancer patients will ... treatment, as well as to improve both pre-infusion ...
Breaking Biology News(10 mins):